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Enabled by high-throughput sequencing approaches, epithelial cancers across a range of tissue types are seen to
harbor gene fusions as integral to their landscape of somatic aberrations. Although many gene fusions are found at
high frequency in several rare solid cancers, apart from fusions involving the ETS family of transcription factors
which have been seen in approximately 50 % of prostate cancers, several other common solid cancers have been
shown to harbor recurrent gene fusions at low frequencies. On the other hand, many gene fusions involving
oncogenes, such as those encoding ALK, RAF or FGFR kinase families, have been detected across multiple different
epithelial carcinomas. Tumor-specific gene fusions can serve as diagnostic biomarkers or help define molecular
subtypes of tumors; for example, gene fusions involving oncogenes such as ERG, ETV1, TFE3, NUT, POU5F1, NFIB,
PLAG1, and PAX8 are diagnostically useful. Tumors with fusions involving therapeutically targetable genes such as
ALK, RET, BRAF, RAF1, FGFR1–4, and NOTCH1–3 have immediate implications for precision medicine across tissue
types. Thus, ongoing cancer genomic and transcriptomic analyses for clinical sequencing need to delineate the
landscape of gene fusions. Prioritization of potential oncogenic “drivers” from “passenger” fusions, and functional
characterization of potentially actionable gene fusions across diverse tissue types, will help translate these findings
into clinical applications. Here, we review recent advances in gene fusion discovery and the prospects for medicine.Introduction
Recurrent chromosomal rearrangements in cancers have
been described for over half a century [1, 2]. The
characterization of the oncogenic fusion BCR-ABL1 at
t(9,22) translocation loci in chronic myeloid leukemia,
which culminated in the development of a molecularly
targeted therapy, provides a compelling “bench to bed-
side” paradigm for cancers [3, 4]. Numerous gene
fusions have since been defined at cytogenetically dis-
tinct loci of recurrent chromosomal aberrations in
hematological malignancies and sarcomas, as well as in
solid cancers, albeit much less frequently, arguably
owing to technical limitations in resolving karyotypically
complex, heterogeneous sub-clones in solid tumor tis-
sues [5, 6]. The serendipitous discovery of ETS family
gene fusions in common prostate carcinoma [7, 8], and
of ALK and ROS kinase fusions in lung cancer [9, 10]
through transcriptomic and proteomic approaches,
bypassing chromosomal analyses, provided a strong fillip* Correspondence: chakumar@umich.edu; arul@umich.edu
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and pointed to alternative approaches to gene fusion
discovery. Developments in high-throughput sequencing
techniques over the past decade [11] have made possible
a direct, systematic discovery of gene fusions in solid
cancers [12–14], rapidly revealing a diverse genomic
landscape. Gene fusions have now been identified in
several common carcinomas, including those of the
prostate, lung, breast, head and neck, brain, skin, gastro-
intestinal tract, and kidney, which alongside the widely
documented gene fusions in thyroid and salivary gland
tumors support the notion that gene fusions are integral
to the genomic landscape of most cancers.
Here, we review the emerging landscape of gene fu-
sions across solid cancers, focusing on the recent spurt
of discoveries made through sequencing. We review
common features of “driver” fusions (those that contrib-
ute to tumor progression), the major functional classes
of fusions that have been described, and their clinical,
diagnostic and/or therapeutic implications.article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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The first gene fusions to be defined in solid cancers,
RET/PTC [15] and NTRK1 [16] rearrangements in papil-
lary thyroid carcinoma were identified through a “trans-
formation assay” using cancer genomic DNA transfected
into murine NIH3T3 cells, followed by retrieval and ana-
lysis of human genomic DNA from transformed cells
[17]. More typically, karyotyping and cytogenetic analysis
of recurrent translocations helped define early gene fu-
sions in solid cancers, such as CTNNB1-PLAG1 [18] and
HMGA2 fusions [19] in salivary gland pleomorphic ad-
enomas, PRCC-TFE3 in renal cell carcinomas [20], and
ETV6-NTRK3 fusion in secretory breast carcinoma [21].
Incorporating more molecular approaches, a recurrent
2q13 breakpoint locus, t(2;3)(q13;p25), in follicular thy-
roid carcinoma was fine mapped using yeast artificial
chromosomes, and cloned through 3′ rapid amplifica-
tion of cDNA ends (RACE) of the candidate PAX8
cDNA, leading to characterization of the PAX8-PPARγ
gene fusion [22]. Anticipating high-throughput gen-
omics approaches, an expressed sequence tag (EST)
mapping to the recurrent chromosomal breakpoint at
t(15;19)(q13;13.1) in midline carcinoma was identified
from an EST database and cloned through RACE to
identify the pathognomonic gene fusion BRD4-NUT
[23]. The gene fusions defined in solid cancers thus
far were localized at cytogenetically distinct, recurrent
chromosomal aberrations, and were largely confined
to relatively rare subtypes of solid cancers [5].
However, between 2005 and 2007, independent of a
priori evidence of genomic rearrangements, recurrent
gene fusions involving ETS family genes were discovered
in prostate cancer, based on analysis of genes displaying
outlier expression [7, 8, 24]. Around the same time, a
transformation assay with a cDNA expression library
(not genomic libraries [17]) from a lung adenocarcinomaBox 1. Summary points
1. Gene fusions are an integral component of the landscape of somat
2. Recurrent 5′ fusion genes are generally lineage- and/or cell-type sp
3. Recurrent 3′ fusion genes in epithelial cancers are usually kinases or
soft tissue cancers.
4. High-throughput sequencing enables systematic discovery of gene
5. High-throughput sequencing often identifies multiple gene fusions
oncogenic “driver” from unimportant “passenger” aberrations.
6. Chimeric RNAs expressed independent of chromosomal rearrangem
7. Functionally recurrent gene fusions provide clinically relevant molec
tumors.
8. Functionally recurrent gene fusions that are seen across tissue type
9. Gene fusions represent personalized therapeutic targets and prognsample led to the discovery of EML4-ALK fusions [10],
and a high-throughput phosphotyrosine signaling screen
of lung cancer cell lines and tumors identified SLC34A2-
ROS1 fusions in non-small-cell lung carcinoma (NSCLC)
[9]. Thus, analyses of cancer RNA and proteins provided
a critical breakthrough in the identification of oncogenic
gene fusions in common carcinoma. In Fig. 1, we
summarize the timeline of gene fusion discoveries,
100 years since Boveri’s prescient hypothesis that malignant
tumor growth is a consequence of chromosomal abnor-
malities, including “combinations of chromosomes” [25].
Next-generation sequencing
High-throughput sequencing of tumor samples provides
a direct readout of chimeric sequences corresponding to
putative gene fusions, and the available depth of cover-
age helps uncover even relatively minor, sub-clonal
events. In a proof of principle study, high-throughput
genomic sequencing was used to identify several gene
fusions in a panel of breast cancer cell lines and tissues
[14]. However, considering that only a small subset of
genomic breakpoints correspond to gene fusions encod-
ing fusion transcripts or proteins, alternative approaches
were explored. In a directed approach, focusing on
chimeric transcripts as the readout of “expressed” gene
fusions, Maher and colleagues used coupled short- and
long-read transcriptome sequencing [12] and paired-end
transcriptome sequencing [13] to detect chimeric RNAs
that could be analyzed to characterize gene fusions.
RNA sequencing has since been widely used in the dis-
covery of numerous gene fusions in diverse epithelial
cancers. Additionally, paired-end tag [26] and chromatin
interaction analysis by paired-end-tag sequencing have
been employed for gene fusion discovery [27], as well as
phosphoproteome analysis, as in the discovery of a
SND1-BRAF fusion in a gastric carcinoma sample [28].ic aberrations in all cancers.
ecific.
transcription factors, similar to the situation in hematological and
fusions with high sensitivity and precision.
in individual samples, presenting a challenge to distinguish
ents are frequently observed in cancer (and benign) tissues.
ular subclassifications of existing morphological categories of
s define functionally distinct molecular subtypes of cancers.
ostic and diagnostic markers.
Fig. 1 Timeline of gene fusion discoveries. A timeline representation of salient gene fusion discoveries starting with 1914, the year that marked
the publication of Boveri’s monograph “Zur Frage der Entstehung maligner Tumoren”, in which he proposed that aberrant “combinations of
chromosomes” underlie malignant transformation [25]. The top bar shows recurrent chromosomal rearrangements or gene fusions in hematological
(purple) and soft tissue (green) malignancies, and the bottom bar shows gene fusions in relatively rare (blue) and those in common (red) epithelial
cancers. ACC adenoid cystic carcinoma, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, APL acute promyelocytic leukemia, cholangio
cholangiocarcinoma, CML chronic myeloid leukemia, CRC colorectal carcinoma, MLL mixed lineage leukemia, PLGA pediatric low grade astrocytoma,
Ph Philadelphia chromosome
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as commonly used as RNA sequencing, likely owing to
several additional, specialized steps that are involved.
Interestingly, RNA sequencing has also identified a
class of chimeric RNAs that do not involve chromo-
somal aberrations. For example, “read-through” chimeric
SLC45A3-ELK4 transcripts, such as those detected in
prostate cancer, result from runaway transcription of the
androgen-inducible, prostate-specific gene SLC45A3 into
ELK4, the adjacent ETS family gene in the same orienta-
tion [12, 29–31]. Similarly, the VTI1A-TCF7L2 fusion,
originally identified through genomic sequencing ofcolorectal carcinoma (CRC) samples [32], was found in a
follow-up study using RNA analyses to be quite preva-
lent in other cancers, as well as in benign samples [33].
Chimeric transcripts not associated with genomic trans-
location have also been observed between non-contiguous
genes. Guerra and colleagues identified CCND1-
TACSTD2 (TROP2) chimeric mRNA that involves genes
located on different chromosomes in subsets of ovarian,
breast, gastrointestinal, and endometrial cancers [34]. The
functional significance of these RNA chimeras is not clear
at present, as their expression is typically seen to be rela-
tively non-specific.
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High-throughput sequencing of cancer samples frequently
identifies multiple gene fusions in individual samples,
often presenting a challenge for identifying potentially
oncogenic driver fusions among irrelevant passenger aber-
rations. Some useful generalizations have emerged from
multiple analyses: first, driver fusions are typically marked
by a continuous open reading frame (ORF) that retains
functional domains, such as the kinase domain in gene fu-
sions involving oncogenic kinases, or DNA-binding do-
mains in the case of transcription factors; second, some
fusions display loss of auto-inhibitory domains (for ex-
ample, loss of the N-terminal inhibitory domain in the
product of BRAF fusions, or loss of 3′ UTR sequences in
FGFR or HMGA2 fusions that serve as binding sites for
inhibitory microRNAs). Yet other types of fusions juxta-
pose the promoter of certain tissue-specific, inducible or
highly expressed genes; for example, the prostate-specific,
androgen-inducible genes TMPRSS2 or SLC45A3 fused in
frame with the proto-oncogenes ERG or BRAF, respect-
ively, generate the TMPRSS2-ERG and SLC45A3-BRAF
gene fusions in prostate cancer.
In the case of novel gene fusions involving less charac-
terized genes, distinguishing candidate driver fusions
from random events is complicated by the many false
positive candidates resulting from alignment artifacts,
such as multi-mapping of reads owing to homologous
(pseudogenes) and/or repetitive sequences, and sequencing
artifacts due to errors in library generation (particularly
ligation and PCR artifacts) and sequencing. Incorporating
these considerations, and additional bioinformatics filters,
various bioinformatics pipelines have been developed to
help prioritize fusion candidates from next-generation
sequencing (NGS) data, including Chimerascan [35],
FusionSeq [36], DeFuse [37], TopHat-Fusion [38], PRADA
[39], and JAFFA [40]. While useful to help reduce the
number of false candidates, the output from bioinformatics
pipelines needs to be further validated, preferably followed
by functional assays, before designating candidate gene fu-
sions as novel driver aberrations. Recurrence of fusions, fu-
sion partners or partner gene families in gene fusion
databases also helps to prioritize candidate fusions. Once
validated, screening for novel gene fusions in larger cohorts
of samples employs quantitative RT-PCR or more recent
techniques such as nano-string-based detection [41–43].
Overview of the landscape of gene fusions in
epithelial cancers
From the first reported chromosomal rearrangements in
the 1960s up to the year 2000 (roughly marking the
advent of high-throughput molecular techniques), the
Mitelman Database of Chromosome Aberrations and
Gene Fusions in Cancer catalogued more than 600 “re-
current balanced neoplasia-associated aberrations”, inwhich solid cancers accounted for less than 20 % [44]; in
its latest update (7 May 2015), this database lists 10,004
“gene fusions” [45], with solid cancers accounting for a
much greater proportion, and with a large number of
these fusions identified by recent high-throughput gene
expression or sequencing analyses. Over the last decade,
numerous gene fusions have been characterized in di-
verse solid cancers, including ETS family gene fusions in
prostate cancer [7, 8, 12, 30, 46–56]; ALK, ROS1 and
RET kinase fusions in lung cancer [9, 10, 57–69]; RAF
kinase fusions in brain tumors [70–80], melanoma [81,
82], gastric cancer [28, 82], and prostate cancer [82, 83];
R-spondin fusions in colorectal and prostate cancer [83,
84]; CD44-SLC1A2 gene fusions in gastric cancer [85];
MAST- and NOTCH-family gene fusions in breast can-
cer [86]; MITF gene fusions in renal cancer [87]; and a
number of FGFR family fusions in diverse cancer types
[88] (Table 1). More than 8000 gene fusions across 16
different tumor types are tabulated in The Cancer Genome
Atlas (TCGA) Fusion gene Data Portal (http://www.
tumorfusions.org) [89]. The key points regarding gene
fusions in epithelial cancers are summarized in Box 1.
These gene fusions in solid cancers encompass the
diversity of fusion architectures, as shown in Fig. 2 and
Box 2, and represent a spectrum of functional categories,
including those described earlier such as kinases and tran-
scription factors, as well as those involving newer pathways
and loss-of-function fusions (discussed later). Notably,
even as numerous novel gene fusions are being discovered
fairly rapidly, most of these are either non-recurrent single-
tons, or are seen to recur at exceedingly low frequency in
tumor subtypes or to recur across tumor types (Table 1).
Incidentally, gene fusions displaying molecular recurrence
involving both 5′ and 3′ partner genes, as in TMPRSS2-
ERG, EML4-ALK, and BRD4-NUT, are relatively few. A
large number of fusions display recurrence of a fusion gene
in combination with multiple different partners; for ex-
ample, BRAF/RAF1 [76, 79, 82, 83] and FGFR1/2/3 [88–
94] are fused to several different 5′ partners across differ-
ent tissue types (Additional file 1). This heterogeneity is
likely reflective of the diverse tissue–physiological milieu in
which these oncogenes impart selective advantage to the
cancer cells. Conversely, some lineage-specific genes are
seen to serve as 5′ partners across multiple different 3′
genes; for example, TMPRSS2 and SLC45A3 in prostate
cancer have been observed as 5′ partners of ERG, ETV1,
ETV4, ETV5, BRAF, and ELK4 (Table 1 and Additional file
1). Another type of observed “recurrence” involves iso-
forms of a gene family — for example, ETV1/2/3/4/5,
FGFR1/2/3, BRAF/RAF1, BRD3/4, CRTC1/CRTC3, and
NTRK1/3— as fusion partners. Considering that individual
fusions may be observed relatively rarely (even uniquely),
the potential functional consequences of gene fusions
assumes priority over considerations of recurrence.
Box 2. Mechanisms of generation of gene fusions
An overview of the genomic architecture of gene fusions reveals that fusions may result from insertion, deletion, inversion, or tandem
duplication or amplification, and may involve the same chromosome (intra-chromosomal) or different chromosomes (inter-chromosomal)
(Fig. 2). A majority of chromosomal rearrangements have been associated with intra-chromosomal tandem duplications and amplifications in
multiple whole-genome sequencing studies [14, 26, 80, 150]. Micro-homologies and repeat elements have been associated with loci of
recurrent break points [151]. In an analysis of RAF family gene fusion breakpoints in low-grade astrocytomas, tandem duplications generated
by microhomology-mediated break-induced replication were identified as the mechanism of generation of fusions [74].
Spatial proximity between distant chromosomal loci has been associated with chromosomal rearrangements, as observed between RET
and the H4 genes located 30 megabases (Mb) apart on chromosome 10, involved in RET gene fusions in papillary thyroid carcinoma
[152]. This proximity may be induced by genotoxic stress; for example, androgen stimulation coupled with the genotoxic stress of
radiation was shown to generate gene fusions through “induced proximity” between TMPRSS2 and ERG (located on chromosome
21q22.2, approximately 3 Mb apart) as well as between TPMRSS2 and ETV1 (located on chromosome 7) [153, 154] (Fig. 3a).
Another phenomenon, called chromothripsis, describes the frequent occurrence of massive chromosomal aberrations localized to only one
or two chromosomes, with fragments of chromosome joined randomly [155, 156]. Chromothripsis may be responsible for the generation of
numerous, apparently random passenger gene fusions that are retained in the multiclonal cells of epithelial cancers, as well as loss-of-
function fusions involving tumor suppressors, likely involving the non-homologous end-joining DNA repair system (Fig. 3b).
Several cancer-causing viruses, such as Epstein–Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV), human papilloma virus (HPV),
hepatitis B and C viruses (HBV and HCV), and Merkel cell polyomavirus (MCV), integrate into human genomic DNA at defined hotspots as well as
seemingly randomly [157]. Viral integration events have been associated with chromosomal aberrations, such as MYC amplification in HPV-
positive genital carcinoma [158], and not uncommonly, loss of gene function [159, 160] or gene fusions involving viral–human sequences have
been reported [161, 162]. The recent report of a recurrent gene fusion of UBR5 on 8q22.3 and ZNF423 on 16q12.1 (UBR5-ZNF423) in 8 % of EBV-
associated primary nasopharyngeal carcinomas suggests a driver function of this gene fusion in a subset of nasopharyngeal cancers [163].
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Functionally distinct molecular classes of gene fusions
that are shared across tumor types can be identified in
solid cancers.Kinases
Given their therapeutic importance, identification of
gene fusions involving kinases can often signify a clinic-
ally actionable observation. Kinase fusion genes detected
across multiple cancer types include RET, NTRK1,
NTRK3, ALK, ROS1, FGFR1/2/3, and serine threonine
kinases including the RAF family genes BRAF, RAF1,
CRAF, and MAST1/2 (Table 1 and Additional file 1). In
most gene fusions involving kinases, the kinase domain
is retained [95], and this provides a strong filtering
criterion in high-throughput sequencing data analysis.
Analysis of mRNA sequencing data from the TCGA
compendium, comprising 4366 primary tumor samples
from 13 tissue types, revealed kinase fusions involving
ALK, ROS, RET, NTRK, and FGFR gene families, which
were detected in several types of cancer: bladder carcin-
oma (3.3 %), glioblastoma (4.4 %), head and neck cancer
(1.0 %), low-grade glioma (1.5 %), lung adenocarcinoma
(1.6 %), lung squamous cell carcinoma (2.3 %), and
thyroid carcinoma (8.7 %) [89].Transcription factors
Gene fusions involving dysregulated expression of tran-
scription factors include ETS family gene fusions, seen
in approximately 50 % of all prostate cancers and prob-
ably one of the most prevalent transcription factor gene
fusions in common epithelial cancers. Among these,
ERG represents the most common fusion partner and
ETV1 the most promiscuous, with a dozen or more
different fusion partners described to date (Additional
file 1) [24, 96].
Other gene fusions involving transcription factors
include NUT (or NUTM1), POU5F1, MAML2, NFIB,
PLAG1, TFE3, NOTCH, and PAX8 fusions, imparting
spatially and/or stochastically dysregulated expression in
multiple different cancer types. NOTCH1 and NOTCH2
fusions result in dysregulated transcriptional outcomes,
because after ligand activation, the NOTCH intracellular
domain (NICD) forms a transcriptional activator com-
plex, activating genes involved in differentiation, prolifer-
ation and apoptosis, and those associated with
carcinogenesis. MAML2 acts as a transcriptional co-
activator for NOTCH proteins by amplifying NOTCH-
induced transcription of HES1. TFE3, which belongs to
the MITF/TFE family of basic helix-loop-helix leucine
zipper transcription factors, is involved in TGF-β-
induced transcription, and has important roles in cell
Table 1 Recurrent gene fusions in epithelial cancers of different body tissues and their role as clinical biomarkers
Tissue or body
region
Tumor type Aberration Genetic alteration Diagnostic/prognostic/therapeutic significance Reference
Thyroid gland Papillary thyroid cancer (PTC)
(>80 % of thyroid cancers)
RET gene fusions Multiple different 5′ partners (most common
being CCDC6 (PTC1) and NCOA4 (PTC3)) fuse to 3′
partner RET
10–30 % of PTC cases. RET is an oncogenic
receptor tyrosine kinase sensitive to FDA-
approved drugs, including vandetanib and
cabozantinib
[15]
NTRK1 gene fusions 5′ activating gene partners including TPM3, TPR
and TGF fuse with 3′ partner NTRK1
5 % of PTC cases. NTRK1 is an oncogenic receptor
tyrosine kinase, potentially targetable by kinase
inhibitors
[15, 16]
ETV6-NTRK3 Chromosomal translocation t(12;15) (p13;q25)
generates the fusion, with the dimerization
domain of ETS family transcription factor (TF) ETV6
fused to the tyrosine kinase domain of NTRK3.
Involves exon 14 of NTRK3, unlike other ETV6-
NTRK3 fusions, which involve exon 13
Radiation-associated PTC (14.5 % post-Chernobyl);
2 % of sporadic PTC cases. Second only to RET
fusions in prevalence
[121]
Radiation-induced PTC AKAP9-BRAF In-frame fusion between exons 1–8 of the AKAP9
gene and exons 9–18 of BRAF protein kinase
gene, lacking the auto-inhibitory N-terminal domain
Fusion-positive tumors lack BRAF-activating point
mutations. Fusion causes constitutive activation of
BRAF and downstream MAPK pathways. Thus, a
potential target for MEK inhibitors
[70]
Follicular thyroid carcinoma (FTC)
(10–20 % of thyroid cancers)
PAX8-PPARγ Chromosomal translocation t(2;3)(q13;p25) results
in chimeric protein involving the DNA-binding
domain of the thyroid-specific TF PAX8 fused to
PPARγ
Fusion-positive FTCs appear to have a significantly
better prognosis compared with those lacking this
fusion. FTC cells expressing PAX8–PPARγ fusion
protein show reduced tumor progression in a
mouse xenograft model
[22, 122]
Head and neck Pleomorphic adenoma PLAG1 gene fusions Multiple 5′ partners (CHCHD7, CTNNB1, FGFR1, LIFR,
TCEA1) fuse to 3′ PLAG1
PLAG1 encodes a zinc finger TF that regulates
IGF2 mitogenic signaling pathway
[18, 91]
HMGA2 gene
fusions
HMGA2 is fused with different 3′ partners
(including FHIT, NFIB, and WIF1)
The fusion retains all the functional domains of
HMGA2, and removes the 3′ UTR sequence that
contains several inhibitory let7 microRNA binding
sites. Absence of the Let-7-regulated 3′ UTR in the
fusion transcript results in overexpression of
HMGA2 that is sufficient for neoplastic
transformation
[19]
FGFR-PLAG1 FGFR is the 5′ partner, which, without its kinase
domain, provides the promoter to drive the
expression of the 3′ partner, PLAG1
This FGFR fusion product does not include the
FGFR kinase domain, and therefore is not a target
for FGFR inhibitors
[91]
Adenoid cystic carcinomas (salivary
glands, lacrimal glands, ceruminal
glands; also breast)
MYB-NFIB Inter-chromosomal gene fusion generating a
chimeric transcript comprising almost the entire
reading frame of the MYB oncogene fused to the
last two exons of NFIB
MYB likely provides the oncogenic activity, while
NFIB primarily replaces a potentially inhibitory 3′
UTR of MYB
[119, 120]
Acinic cell carcinoma,
cystadenocarcinoma, mammary
analogue secretory carcinoma of
salivary glands (MASC)
ETV6-NTRK3 (TEL-
TRKC)
Chromosomal translocation t(12;15) (p13;q25)
generates the ETV6-NTRK3 fusion, with the
dimerization domain of the ETS family TF ETV6
fused to the tyrosine kinase domain of NTRK3
This fusion is now considered pathognomonic of
MASC
[103]
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Table 1 Recurrent gene fusions in epithelial cancers of different body tissues and their role as clinical biomarkers (Continued)
Mucoepidermoid carcinoma (MEC) in
the oral cavity (also lung, cervix and
thyroid glands, and clear cell
hidradenoma of skin)
CRTC1-MAML1 or
CRTC3-MAML2
Generated by chromosomal translocation
t(11;19)(q14–21;p12–13). The product of the 3′
partner MAML2 acts as a co-activator of NOTCH
independent of NOTCH ligand to impart the
oncogenic phenotype.
The CRTC-MAML2 fusion is restricted to MEC and
has been associated with favorable prognosis.
[107, 108,
110–114,
116, 117]
Midline anatomical
structures
Nut midline carcinoma (NMC) BRD-NUT 75 % of NMCs express BRD4-NUT fusion proteins,
the rest harbor BRD3 or other 5′ partner genes
fused to NUT. BRD-NUT fusion proteins contain
the N-terminal BET bromodomain, extraterminal
domain, and nuclear localization signal fused to
the entire coding region of NUT protein that con
tains a histone acetyltransferase binding domain
NMC is a rare but aggressive squamous cell
carcinoma originating from midline anatomical
structures such as the head, neck or mediastinum
(including the bladder, thymus, lung, and
skeleton) that is defined by the presence of BRD-
NUT fusions. BRD proteins have recently emerged
as promising therapeutic targets
[104, 105]
Kidney Renal cell carcinoma (RCC) TFE3 gene fusions Translocations at the Xp11.2 breakpoint result in
gene fusions involving the TFE3 gene with various
5′ partners (ASPSCR1, PRCC, NONO, CLTC, and SFPQ)
15 % of patients with RCC aged <45 years have
this aberration. Fusion-positive RCCs in older
patients are more aggressive
[20, 87]
ALK fusions In VCL-ALK fusions, the 3′ portion of the ALK
transcript encoding the kinase domain is fused in
frame to the 5′ portion of VCL
Found in pediatric RMC that affects young black
individuals with the sickle cell trait. In two
independent reports, RMC tumors from three
cases of African–American children with sickle cell
anemia were found to harbor the VCL-ALK fusion
[125, 126]
Non-clear cell renal cell carcinoma
(nccRCC)
CLTC-TFEB This encodes an in-frame fusion protein containing
the conserved bHLH domain of TFEB (similar to
other fusions involving TFEB), and is associated with
the “MITF high” phenotype
Associated with high expression of the anti-
apoptotic protein BIRC7, thus potentially sensitive
to apoptosis-sensitizing BIRC7 inhibitors that are
under development
[88]
ACTG1-MITF In this fusion protein the first 118 amino acids of
MITF are replaced by the N-terminal 121 amino
acids of ACTG1
Although found in only one sample, ectopic
expression of the ACTG1-MITF fusion led to cellular
transformation, suggesting a potential driver
function
[87]
Prostate Prostate cancer TMPRSS2-ERG The 5′ partner TMPRSS2 contributes prostate-
specific, androgen-inducible upstream regulatory
elements fused to the 3′ partner, encoding
oncogenic ETS family TF ERG
Probably the most prevalent gene fusion in
epithelial carcinoma, with 40–50 % of localized
prostate cancers found to harbor this fusion
across multiple independent cohorts around the
world. Associated with prostate carcinogenesis
and distinct clinical correlates compared with
fusion-negative prostate cancers
[7, 8, 46–52]
Fusions involving
other ETS family
genes, including
ETV1, ETV4, ETV5,
ELK4, and FLI1
5′ partners include androgen-inducible genes such
as TMPRSS2, SLC45A3, and FLJ35294, and
androgen-repressed C15ORF21, or housekeeping
genes such as HNRPA2B1 and DDX5, fused to
multiple 3′ oncogenic ETS family TF genes
Together these represent 10–20 % of localized
prostate cancers
[7, 8, 24,
53–56]
RAF gene fusions
(SLC45A3-BRAF and
ESRP1-RAF1)
SLC45A3 is a prostate-specific, androgen-inducible
gene fused upstream to gene encoding
N-terminal-truncated BRAF, resulting in constitutive
activation of this potent oncogene
Although rare, BRAF/RAF1 fusions represent
therapeutic targets
[82, 83]
TMPRSS2-SKIL,
SLC45A3-SKIL, MIPEP-
SKIL, PIPOL1-SKIL,
5′ partners TMPRSS2, SLC45A3, and ACPP contribute
prostate-specific, androgen-inducible upstream
SKIL fusions are observed in 1–2 % of prostate
cancers and potentially upregulate the TGF-β
pathway
[101]
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ACPP-SKIL,
HMGN2P46-SKIL
regulatory elements fused to 3′ partner SKIL, a
negative regulator of SMAD
TBXLR1-PIK3CA,
ACPP-PIK3CB
Index cases with PIK3CA/B fusions show outlier
expression of PIK3CA/B. ACPP imparts androgen-
responsive expression to PIK3CB
PIK3CA fusions may be responsive to PIK3CA
inhibitors
[83]
GRHL2-RSPO2 Index cases with RSPO2 fusions/rearrangements
show outlier expression of RSPO2
RSPO2 is an agonist of the Wnt pathway and
therefore may be responsive to porcupine
inhibitors
[83, 142]
Lung Lung cancer ALK gene fusions
(most commonly
EML4-ALK, but also
TFG-ALK)
EML4-ALK fusion encodes the N-terminal portion
of EML4 fused to the intracellular portion of ALK,
always retaining the tyrosine kinase domain
EML4-ALK fusion is reported in 3–7 % of patients
with NSCLC in different cohorts. ALK-fusion-
positive lung cancers are sensitive to the FDA-
approved kinase inhibitor crizotinib
[10, 59–63,
65, 66]
ROS1 gene fusions Multiple 5′ partners such as TPM3, SDC4, SLC34A2,
CD74, EZR, LRIG3, and GOPC fused to ROS1. All of
the fusion proteins retain the kinase domain of
ROS1
2 % of lung cancer samples in one study [9, 43, 58,
65]
RET gene fusions Multiple isoforms of KIF5B-RET and CCDC6-RET. All
of these products retain the kinase domain of RET
Lung cancer cases with RET fusions may be
candidates for FDA-approved RET inhibitor therapies
such as vandetanib and cabozantinib
[64–69]
Mammary gland Breast cancer ETV6-NTRK3 (TEL-
TRKC)
Chromosomal translocation t(12;15) (p13;q25)
generates ETV6-NTRK3 fusion, with the
dimerization domain of the ETS family TF ETV6
fused to the tyrosine kinase domain of NTRK3
Almost 100 % of secretory breast carcinomas.
ETV6-NTRK3 chimeric protein activates the IRS1
adapter protein, RAS-MAP kinase and PI3K-AKT
pathways, and suppresses TGF-β signaling. ETV6-
NTRK3-expressing cells and tumors are sensitive to
the IGIFR/INSR kinase inhibitors BMS-536924 and
BMS-754807 (currently in clinical trials)
[21, 142]
MAST1 and MAST2
gene fusions
5′ partners including ZNF700, NFIX, and TADA2A
fused to MAST1. ARID1A and GPBP1L1 fused to
MAST2 serine/threonine kinase. All MAST fusions
encode contiguous open reading frames, some
retaining the canonical serine/threonine kinase
domain, all retaining the PDZ domain and a 3′
kinase-like domain
3 % of breast cancer samples in one study [86]
NOTCH gene
fusions
SEC16A-NOTCH1, SEC22B-NOTCH2, NOTCH1 exon
2–exon 28 (intramolecular rearrangement)
NOTCH fusions retain the NOTCH intracellular
domain, which mediates downstream NOTCH
signaling. The SEC16A-NOTCH1 fusion retains the
γ-secretase cleavage site and shows sensitivity to
γ-secretase inhibitors compared with SEC22B-
NOTCH2, which loses this site
[86]
EML4-ALK EML4 exon 13 fused to ALK exon 20, similar to
NSCLC fusions
One exon array profiling study reported EML4-ALK
fusions in 2.4 % of breast carcinomas (5 of 209).
One EML4-ALK fusion was detected in
inflammatory breast cancer
[82, 124]
Stomach Gastric cancer RAF gene fusions AGTRAP-BRAF: N-terminal protein AGTRAP fused to
the C-terminal kinase domain of BRAF. SND1-BRAF:
Both these fusions retain the kinase domain of
BRAF, indicating potential responsiveness to RAF/
MEK inhibitors
[28, 82]
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Table 1 Recurrent gene fusions in epithelial cancers of different body tissues and their role as clinical biomarkers (Continued)
5′ SND1 gene fused to BRAF, found in GTL16 gastric
cancer cell line
CLDN18-ARHGAP26 CLDN18 on 3q22.3 fused to ARHGAP26 on 5q31.3.
The fusion protein loses the PH domain of
ARHGAP26, but retains the Rho-GAP and SH3
domains
3 % of Southeast Asian gastric cancers [27]
CD44-SLC1A2 Fusion involving adjacent genes (lying in opposite
orientations on chromosome 13p)
1–2 % of gastric cancers [85]
Gut Colorectal cancer (CRC) EIF3E-RSPO2, PTPRK-
RSPO3
Both these fusion proteins retain the functional
domain of the R-spondins, which are known to be
agonists of the canonical Wnt/β-catenin signaling
pathway
Recurrent fusions involving R-spondin family
genes, EIF3E-RSPO2 (two cases) and PTPRK-RSPO3
(five cases) were detected by RNA sequencing of
68 “microsatellite stable” subtype CRC samples
[85]
LACTB2-NCOA2 The fusion disrupts expression of NCOA2, which is
an inhibitor of the Wnt/β-catenin pathway. This
loss-of-function fusion thus represents a novel
oncogenic mechanism in a subset of CRC
Found in 6 of 99 (6.1 %) CRC cases [103]
VTI1A-TCF7L2, RP11-
57H14.3- TCF7L2
Gene fusion involving activator of Wnt/β-catenin
signaling pathway. VTI1A-TCF7L2 fusion lacks the
TCF4 β-catenin-binding domain
VTI1A-TCF7L2 was found in 3 of 97 CRCs. A screen
for TCF7L2 fusion transcripts revealed its presence
in more than 80 % of CRCs, 29 % of normal
colonic mucosa, and 25–75 % of normal tissues
from other organs. Thus, TCF7L2 fusion transcripts
are neither specific to cancer nor to the colon or
rectum. TCF7L2 fusion transcripts represent “read
through” events
[32, 33]
Skin Melanoma BRAF and RAF1
gene fusions
Diverse N-terminal proteins fused to the BRAF/RAF
kinase domain
Seen in 3 % of melanomas; fusions retain the
kinase domain of BRAF, indicating potential
responsiveness to RAF/MEK inhibitors
[82]
Other, non-
recurrent
aberrations
RB1-ITM2B, PARP1-MIXL1, RECK-ALX3, TMEM8B-TLN1,
CCT3-C1orf61, GNA12- SHANK2, ANKHD1-C5orf32
11 novel gene fusions were identified in 6 different
patient samples, including both inter- and
intra-chromosomal events. These fusions encode
putative dominant-negative proteins (RB1, PARP1),
and a truncated inhibitor of tumor invasion and
metastasis (RECK)
[81]
Central nervous
system
Gliomas PTPRZ1-MET The fusion involves translocation of introns 3 or 8
of PTPRZ and intron 1 of MET
Found only in grade III astrocytomas (1/13; 7.7 %)
or secondary GBMs (3/20; 15.0 %)
[71]
Pilocytic astrocytoma BRAF/RAF1 gene
fusions
KIAA1549-BRAF, FAM131B-BRAF, SRGAP3-RAF1 Most frequently observed in pediatric brain
tumors. Approximately 80 % of pilocytic
astrocytomas and other low-grade gliomas harbor
the KIAA1549-BRAF gene fusion
[72–80]
FDA Food and Drug Administration, FTC follicular thyroid carcinoma, GBM glioblastoma multiforme, MASC mammary analog secretory carcinoma of salivary glands, MEC mucoepidermoid carcinoma, nccRCC non-clear-cell renal
cell carcinoma, NMC NUT midline carcinoma, NSCLC non-small-cell lung carcinoma, PTC papillary thyroid cancer, RCC renal cell carcinoma, RMC renal medullary carcinoma, TF transcription factor
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Fig. 2 Diversity in the architecture of gene fusions. Schematic representation of different patterns of chromosomal rearrangements inferred from
chimeric transcripts. Exons of genes involved in fusions are shown in blue and orange, and their transcriptional orientation is denoted by arrows.
The likely mechanisms of chimera generation are indicated. Chr chromosome
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somal translocations that result in various gene fusions
(such as PRCC-TFE3, RCC17-TFE3, PSF-TFE3, NON-
O(p54nrb)-TFE3 and ASPL-TFE3) in papillary renal cell
carcinomas. PLAG1 is an oncogenic transcription factor
associated with the neoplastic transformation of pleo-
morphic adenomas of the salivary gland and lipoblastomas
through upregulation of IGF2, CRLF1, CRABP2, CRIP2,
and PIGF. NFIB binds viral and cellular promoters activat-
ing transcription and replication. POU5F1 and PAX8 are
homeobox-containing transcription factors, a family of
genes that play a role in cell fate and differentiation pro-
grams, and whose role in cancer is well recognized, particu-
larly PAX8 in thyroid cancer [22].Other functional classes
Metabolic enzymes
CD44-SLC1A2/EAAT2 gene fusions are detected in 1–
2 % of gastric cancers involving the glutamate transporter
SLC1A2 [85], and cause intracellular accumulation of glu-
tamate, a growth-promoting amino acid associated with
oncogenic functions [97, 98]. Thus, this gene fusion
may be establishing a pro-oncogenic metabolic milieu,
akin to the increased levels of sarcosine reported in
prostate cancer [99].
Wnt/β-catenin signaling pathway
RNA sequencing of 68 “microsatellite stable” subtype
colorectal cancer samples revealed two recurrent fusions
Inter chromosomal
Intra chromosomal
Ligand Co-activator Receptor
DNA PKCs DNA ligase Ku70–Ku80
Intra/Inter chromosomal
(a)
(b)
Fig. 3 Schematic illustration of the molecular mechanisms underlying the formation of gene fusions. a “Induced proximity”, or chromosomal
proximity induced by receptor–ligand co-activator-mediated transcription between genes on the same chromosome (intra-chromosomal) or
different chromosomes (inter-chromosomal). Physical proximity accompanied by a chromosomal break during transcription or mediated by
genotoxic stress can lead to aberrations in DNA repair, which, in turn, may cause the formation of gene fusions. b Fusions may result from
aberrant DNA double-strand break repair involving alternative-non-homologous end joining machinery. PKC protein kinase C
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cases and PTPRK-RSPO3 in five cases [84]. Both these
gene fusions retained the functional domain of the R-
spondins that are known to be agonists of the canonical
Wnt/β-catenin signaling pathway. Additionally, the
LACTB2-NCOA2 chimeric transcript detected in 6 of 99
(6.1 %) colorectal cancer cases led to disruption of NCOA2
expression, thus activating the Wnt/β-catenin pathway
[100]. Recently, R-spondin fusions such as GRHL2-RSPO2
were described in prostate cancer as well [83].TGF-β pathway
Recently, fusions involving SKIL (which encodes a
SMAD inhibitor) 3′ to androgen-regulated promoters
such as TMPRSS2, SLC45A3, and ACPP, were found in 6
of 540 (1.1 %) prostate cancers and one cell line xeno-
graft, LuCaP-77 [101]. SKIL overexpression in these
tumors was associated with upregulation of the TGF-β
pathway, likely providing the oncogenic mechanism in
these tumors.Chromatin modifier genes
In an analysis of fusion transcripts observed in TCGA
data across multiple tumor types, fusions involving chro-
matin modifier genes, including histone methyltransferase
and histone demethylase genes, were identified in 111
samples (2.5 %) [89]. Chromatin modifier genes are poten-
tial therapeutic targets and these gene fusions thus repre-
sent a novel class of potentially actionable aberrations.Further functional classes
Additional classes of genes represented among recurrent
fusions in solid cancers include those encoding growth
factor receptors (GABBR2, TACSTD2, ITPR2), adaptors
and co-factors (WIF1, GAB2), Ras-Gap proteins (DOCK5,
ARHGAP15), and cytoskeletal proteins (SNF8, SEC22B,
HIP1R, STXBP4, MYO19, TPR). Although some of these
fusions are scored as recurrent, they may represent
passenger mutations associated with loci of recurrent
chromosomal aberrations, while others may define tissue-
specific or cooperative roles.
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While most reported gene fusions pertain to gain-of-
function aberrations imparting neoplastic phenotypes,
with high-throughput sequencing, fusions resulting in loss
of function of tumor suppressors such as TP53 and PTEN
have been identified as well [102]. The LACTB2-NCOA2
fusion in colorectal cancer leads to disruption of NCOA2,
which encodes an inhibitor of the Wnt/β-catenin pathway
[100], thus acting to promote carcinogenesis.
Gene fusion signatures in personalized medicine
of epithelial cancers
Some gene fusions are associated with distinct subtypes
of carcinoma, while others have been detected across
different tissues or lineages, defining molecular subsets
of cancers transcending morphological distinctions.
Recurrent gene fusions as biomarkers of subtypes of solid
cancers
Some of the salient gene fusions that define molecular
subtypes of epithelial cancers within specific organs or
tissue types are summarized in Table 1. The ETV6-
NTRK3 fusion is a diagnostic biomarker of secretory
breast carcinoma, as well as the acinic cell carcinoma or
cystadenocarcinoma recently designated as “mammary
analog secretory carcinoma of salivary glands” (MASC)
[21, 103]. BRD-NUT fusions define NUT midline carcin-
oma [104, 105]. CRTC-MAML2 fusions are the defining
molecular aberration of mucoepidermoid carcinoma
(MEC) [106, 107]; translocation-negative MECs are pro-
posed to be designated as a distinct subgroup of adenos-
quamous carcinoma [108]. CRTC-MAML fusions are
also found in MEC of the lung [109–112], cervix [113],
thyroid glands and oral cavity [114], as well as in clear
cell hidradenoma of the skin [115, 116]. In all cases,
MAML2 fusions characterize benign or low-grade tu-
mors, and for reasons not described so far have been as-
sociated with a favorable prognosis [117]. Interestingly,
pulmonary MECs have shown clinical response to gefi-
tinib in the absence of sensitizing EGFR mutations, sug-
gesting a potential connection with CRTC-MAML2 and
the possibility of therapeutic application in other MECs
harboring this fusion [110, 118]. The diagnostic subclass
of adenoid cystic carcinomas, including salivary gland
and breast cancer, is characterized by MYB-NFIB gene
fusions [119, 120]. Fusions defining subtypes within a
cancer include RET and NTRK gene fusions in subsets of
papillary thyroid carcinoma [121], while PAX8-PPARγ
fusions characterize subsets of follicular thyroid carcin-
oma [22, 122]. ETS family gene fusions, primarily in-
cluding ERG (and less frequently, ETV1, ETV4, ETV5 or
FLI1), are found in approximately 50 % of prostate can-
cers, the most common fusion being TMPRSS2-ERG.
The EWSR1-ATF1 fusion found in hyalinizing clear cellcarcinoma of the salivary glands, a rare and indolent
tumor, can potentially be used as a molecular marker of
this subtype that is histologically similar to the more
aggressive MEC [123].
Gene fusions or fusion partners found across tissue
types are common in solid cancers. The EML4-ALK
fusion, initially identified in lung cancer [9, 10] has since
been reported in breast cancer [124], colorectal carcin-
omas [66, 124], and in pediatric renal medullary carcin-
oma that affects young African–Americans with the
sickle cell trait [125, 126]. Similarly, RET fusions, first
characterized in thyroid cancer, are widely observed in
lung cancers, and the EWSR1-POU5F1 fusion was de-
tected in two rare epithelial tumors, hidradenoma of the
skin and MEC of the salivary glands [127].
Gene fusions involving RAF kinase genes (BRAF,
RAF1, CRAF) have been identified in low-grade tu-
mors of the central nervous system (pilocytic astrocy-
tomas and other low-grade gliomas), gastric cancer,
melanoma and prostate cancer. RAF family fusions
involve truncation of the N-terminal auto-inhibitory
domain, thus generating constitutively active RAF
protein. Curiously, BRAF gene fusions in low-grade
astrocytomas have been associated with a tendency to
growth arrest, conferring a less aggressive clinical
phenotype and a better clinical outcome [75, 128].
Additionally, RAF family fusions have been defined
across diverse solid cancers, including prostate, gas-
tric, and skin cancers [82, 83]. A screen for BRAF
gene fusions in 20,573 solid tumors, using the Foun-
dationOne™ targeted gene panel, identified BRAF fu-
sions involving 29 unique 5′ fusion partners in 55
(0.3 %) cases across 12 different tumor types, includ-
ing 3 % (14/531) of melanomas, 2 % (15/701) of gli-
omas, 1.0 % (3/294) of thyroid cancers, 0.3 % (3/
1,062) of pancreatic carcinomas, 0.2 % (8/4,013) of
non-small cell lung cancers and 0.2 % (4/2,154) of
colorectal cancers, as well as single cases of head and
neck cancer, prostate cancer, rectal adenocarcinoma,
ovarian, uterine endometrial, and mesothelioma [70].
Fusions involving FGFR tyrosine kinase family genes
have also been observed across diverse cancers [88]. The
first FGFR fusion observed in epithelial cancers, FGFR1-
PLAG1, was found in a subset of pleomorphic salivary
gland adenomas, and involves FGFR1 as the 5′ partner
upstream of PLAG1, the known driver of salivary gland
tumors [91]. Curiously, this fusion excludes the tyrosine
kinase domain of FGFR. Fusions that retain the tyrosine
kinase domain of FGFR include FGFR3-TACC3 in glio-
blastoma [92, 129]. Subsequently, diverse FGFR fusions,
all retaining the tyrosine kinase domain, have been ob-
served in bladder, lung, breast, thyroid, oral, and prostate
cancers, involving FGFR1, 2, or 3 either as the 5′ or 3′
partners [88, 94].
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In Additional file 2 we summarize recent clinical trials
involving gene fusions in epithelial cancers. The RET in-
hibitor vandetanib shows antiproliferative activity in
RET-mutant medullary thyroid cancer (MTC) [130], and
was recently approved by the US Food and Drug Ad-
ministration for treatment of metastatic MTC. Sensitiv-
ity to vandetanib was also observed in RET-fusion-
positive papillary thyroid carcinoma [131] and lung can-
cer cells [68, 132]. Treatment with Pfizer’s kinase inhibi-
tor crizotinib (PF02341066) led to a dramatic clinical
response in EML4-ALK-positive NSCLC patients [133,
134], as well as in one patient with an SLC34A2-ROS1-
fusion-positive tumor [58]. Unfortunately, resistance is
inevitably observed, owing to mutations in the kinase
domain [134, 135], or ALK gene fusion amplification,
KIT amplification or increased auto-phosphorylation of
EGFR [136]. This is representative of the challenge of
treating solid cancers and argues for the development of
combinatorial therapeutic approaches from the start ra-
ther than sequentially, as is the practice currently. RAF
or MEK inhibitors represent potential precision thera-
peutic options for several solid cancers with the diverse
RAF family gene fusions described earlier. Several FGFR
inhibitors currently in clinical trials represent potential
therapeutics for cancers harboring FGFR fusions across
multiple cancer types, including bladder cancer, prostate
cancer, and others [88, 90, 94, 137]. The rare PIK3C family
gene fusions in prostate cancer (for example, TBXLR1-
PIK3CA and ACPP-PIK3CB) show overexpression of the
PI3KC genes and may be sensitive to PIK3CA inhibitors
[83].
For treatment of secretory breast carcinoma express-
ing the ETV6-NTRK3 fusion, therapeutic targeting of
the downstream signaling axis of IGF1R, using the
IGIFR/INSR kinase inhibitors BMS-536924 and BMS-
754807 that are currently in clinical trials, was found to
be effective [138]. Breast cancer cells expressing NOTCH
fusion products that retain the γ-secretase cleavage site
were sensitive to γ-secretase inhibitor (GSI) in culture,
and treatment with GSI reduced tumor growth in vivo
[86]. On the other hand, breast cancer cells harboring
NOTCH fusions that encode NICD independent of the
γ-secretase cleavage site were insensitive to GSI.
In a recent clinical sequencing study of 102 pediatric
cancers, among 37 non-sarcoma solid cancers, several
functional gene fusions were identified, including TFE3
fusions in a colorectal cancer (SFPQ-TFE3) and renal cell
cancer (ASPSCR1-TFE3) — both cases were treated with
pazopanib, the latter displaying stable disease for
10 months [139].
Efforts to target several other gene fusions are under-
way. The newly developed bromodomain inhibitors thathave shown dramatic efficacy in hematological malig-
nancies [140, 141] are now being tested in multiple
clinical trials for NUT midline carcinoma character-
ized by BRD3/4-NUT gene fusions, which represent a
rare but highly aggressive class of tumors with no
effective treatment currently available [104]. Also, the
R-spondin fusions observed in colorectal and prostate
cancer may be sensitive to Wnt pathway antagonist
porcupine inhibitors [142].
Gene fusions involving ETS transcription factors have
been utilized in diagnostic applications. A non-invasive
assay system has been developed based on the detection
of TMPRSS2-ERG fusion transcripts in urine samples
from patients, which in combination with the detection
of urine PCA3 improved the performance of the multi-
variate Prostate Cancer Prevention Trial risk calculator
in predicting cancer on biopsy [143]. Detection of
TMPRSS2-ERG in circulating tumor cells in therapy-
naive patients and in castration-resistant prostate cancer
patients following treatment suggests potential applica-
tions in non-invasive monitoring of the therapeutic
response [144]. While therapeutic targeting of transcrip-
tion factor oncogenes is intrinsically challenging, on the
basis of the interaction of ERG with the DNA repair
enzyme PARP1 and DNA protein kinase DNA-PKc, use
of PARP inhibitors was shown to inhibit growth
of TMPRSS2-ERG-positive prostate cancer xenografts
[145]. Additionally, PARP inhibition was associated
with radiosensitization of TMPRSS2-ERG-positive pros-
tate cancer cells [146, 147]. These experimental leads
point to possible therapeutic avenues targeting a preva-
lent gene fusion in a common carcinoma.
Perspectives and discussion
Genomic or transcriptomic sequencing has virtually
supplanted molecular and cytogenetic techniques as the
primary modality for discovery of gene fusions, and
detection of gene fusions is increasingly incorporated
into the standard workflow for genomic characterization
of tumors in both research and clinical settings. Tran-
scriptome sequencing has been useful in helping to iden-
tify expressed gene fusions based on evidence of the
fusion of exon boundaries, but putative promoter fusions
that do not generate chimeric transcripts are likely to
go undetected. Furthermore, typically recurrent gene fu-
sions characterized in cancers represent gain-of-function
events arising from the juxtaposition of cell-type- or
lineage-specific regulatory elements and proto-oncogenes,
or novel combinations of functional domains derived from
two proteins that provide combinatorial or additive func-
tionalities to normal genes. However, NGS data also reveal
less frequently described loss-of-function chimeras involv-
ing tumor suppressor genes such as TP53, PTEN, and
others. A systematic analysis of loss-of-function gene
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of tumor suppressors that might be currently going unre-
ported, and could help broaden our understanding of the
role of gene fusions in cancer.
The rapid increase in detection of gene fusions across
cancers has spawned multiple discovery and prioritization
pipelines to help distinguish bona fide functional gene fu-
sions from random chimeras (and experimental artifacts).
However, the development of diverse pipelines following
different analysis parameters underscores a need for
standardization of the vocabulary and information content
in recording and reporting gene fusions, along the lines
of the Minimum Information About a Microarray
Experiment [148, 149]. Furthermore, even as bioinfor-
matics analyses help prioritize fusion candidates, the
“recurrence” of fusion genes and/or retention of func-
tional domains provide the most compelling rationale
for functional characterization.
The detection of distinct gene fusions across subtypes
of common carcinoma also provides a basis for molecu-
lar subclassification of these cancers. Recurrent gene
fusions that characterize distinct subtypes of cancers
include BRD4-NUT in NUT midline carcinoma, ETV6-
NTRK3 in secretory breast carcinoma, CRTC-MAML2
fusions in mucoepidermoid carcinoma, and RAF family
fusions in pilocytic astrocytomas. It is expected that as
more and more carcinomas are analyzed by sequencing,
additional subclasses may be recognized on the basis of
whether the detected molecular aberrations are driver
fusions. Importantly, the emerging landscape of gene
fusions in solid cancers also reveals many gene fusions
involving oncogene families or isoforms that are seen
across multiple tumor types or subtypes, for example,
fusions involving RAF and FGFR family genes. This
supports the notion that a molecular classification of
tumors in terms of driver fusions (or SNVs) may com-
plement histopathological descriptions.
Many oncogenes involved in gene fusions (for example,
RET, BRAF, ALK, NOTCH or PIK3CA/B) are also known
to harbor activating mutations. However, fusions and
mutations tend to be mutually exclusive. This indicates
that either fusions or activating mutations can independ-
ently provide oncogenic function, and that either of these
aberrations may render the tumors sensitive to therapeutic
targeting. Thus, for example, MEK inhibitors that have
been found to be useful for tumors with a BRAF activating
mutation may also benefit tumors with the BRAF fusion.
The development of technologies that enable the
systematic detection of molecular aberrations in cancer
has profound clinical implications, as high-throughput
sequencing of individual tumor samples is expected to
become available as a routine diagnostic modality (as for
whole-body PET scans or MRI) in the not-too-distant
future. Considering the important diagnostic andtherapeutic implications, the integration of approaches for
the detection of driver gene fusions into cancer genomics
pipelines is crucial for precision cancer medicine.
Additional files
Additional file 1: Recurrent gene fusions in epithelial cancers.
Summary of recurrent gene fusions in epithelial carcinoma across
different tissues. a Gene fusions with common 5′ and 3′ genes. b Multiple
5′ partners with common 3′ genes. c Common 5′ gene partners with
multiple 3′ genes. (DOCX 25 kb)
Additional file 2: Clinical trials involving gene fusions in epithelial
cancers. (PDF 287 kb)
Abbreviations
ACC: Adenoid cystic carcinoma; ALL: Acute lymphoblastic leukemia;
AML: Acute myeloid leukemia; APL: Acute promyelocytic leukemia, cholangio
cholangiocarcinoma; CML: Chronic myeloid leukemia; CRC: Colorectal
carcinoma; CRPC: Castration-resistant prostate cancer; EBRT: External beam
radiation therapy; EBV: Epstein–Barr virus; EST: Expressed sequence tag;
FDA: Food and drug administration; FTC: Follicular thyroid carcinoma; GSI:
γ-secretase inhibitor; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HDR: High
dose rate; HPV: Human papilloma virus; KSHV: Kaposi's sarcoma-associated
herpesvirus; MASC: Mammary analog secretory carcinoma of salivary glands;
MCV: Molluscum contagiosum virus; MEC: Mucoepidermoid carcinoma;
MLL: Mixed lineage leukemia; MTC: Medullary thyroid cancer; nccRCC:
non-clear-cell renal cell carcinoma; NGS: Next-generation sequencing;
NICD: NOTCH intracellular domain; NMC: NUT midline carcinoma;
NSCLC: Non-small-cell lung carcinoma; ORF: Open reading frame;
Ph: Philadelphia chromosome; PLGA: Pediatric low grade astrocytoma;
PTC: Papillary thyroid cancer; RACE 3′: Rapid amplification of cDNA ends;
RCC: Renal cell carcinoma; RMC: Renal medullary carcinoma; TCGA: The
Cancer Genome Atlas; TKI: Tyrosine kinase inhibitor; UTR: Untranslated region.
Competing interests
The University of Michigan has filed for a patent on recurrent gene fusions in
prostate cancer and AMC is named as a co-inventor. The technology has
been licensed to Hologic Inc. to develop a molecular diagnostic.
Acknowledgements
We thank Robin Kunkel for help with the artwork for the figures. AMC is
supported by the Doris Duke Charitable Foundation Clinical Scientist Award
and the Prostate Cancer Foundation. AMC is an American Cancer Society
Research Professor and A. Alfred Taubman Scholar. This work was supported
in part by the US National Institutes of Health (R01CA132874), Early Detection
Research Network grant UO1 CA111275, Prostate SPORE grant P50CA69568, the
Department of Defense Era of Hope grant BC075023 (AMC).
Author details
1Michigan Center for Translational Pathology, University of Michigan Medical
School, Ann Arbor, MI 48109, USA. 2Department of Pathology, University of
Michigan Medical School, Ann Arbor, MI 48109, USA. 3Department of
Computational Medicine and Bioinformatics, University of Michigan Medical
School, Ann Arbor, MI 48109, USA. 4Howard Hughes Medical Institute,
University of Michigan Medical School, Ann Arbor, MI 48109, USA.
5Department of Urology, University of Michigan Medical School, Ann Arbor,
MI 48109, USA. 6Comprehensive Cancer Center, University of Michigan
Medical School, Ann Arbor, MI 48109, USA.
References
1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic
human leukocytes. J Natl Cancer Inst. 1960;25:85–109.
2. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II.
Chronic granulocytic leukemia. J Natl Cancer Inst. 1961;27:1013–35.
3. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu
Rev Immunol. 2004;22:247–306.
Kumar-Sinha et al. Genome Medicine  (2015) 7:129 Page 15 of 184. Rabbitts TH. Commonality but diversity in cancer gene fusions. Cell. 2009;
137(3):391–5.
5. Mertens F, Johansson B, Fioretos T, Mitelman F. The emerging complexity of
gene fusions in cancer. Nat Rev Cancer. 2015;15(6):371–81.
6. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as
a linear function of chromosome aberrations in cancer. Nat Genet. 2004;
36(4):331–4.
7. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al.
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate
cancer. Science. 2005;310(5748):644–8.
8. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS,
et al. Distinct classes of chromosomal rearrangements create oncogenic ETS
gene fusions in prostate cancer. Nature. 2007;448(7153):595–9.
9. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of
phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell.
2007;131(6):1190–203.
10. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al.
Identification of the transforming EML4-ALK fusion gene in non-small-cell
lung cancer. Nature. 2007;448(7153):561–6.
11. Mardis ER. A decade's perspective on DNA sequencing technology. Nature.
2011;470(7333):198–203.
12. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, et al.
Transcriptome sequencing to detect gene fusions in cancer. Nature. 2009;
458(7234):97–101.
13. Maher CA, Palanisamy N, Brenner JC, Cao X, Kalyana-Sundaram S, Luo S,
et al. Chimeric transcript discovery by paired-end transcriptome sequencing.
Proc Natl Acad Sci U S A. 2009;106(30):12353–8.
14. Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, et al.
Complex landscapes of somatic rearrangement in human breast cancer
genomes. Nature. 2009;462(7276):1005–10.
15. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al.
PTC is a novel rearranged form of the ret proto-oncogene and is
frequently detected in vivo in human thyroid papillary carcinomas. Cell.
1990;60(4):557–63.
16. Greco A, Miranda C, Pagliardini S, Fusetti L, Bongarzone I, Pierotti MA.
Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce
structurally different thyroid-specific TRK oncogenes. Genes Chromosomes
Cancer. 1997;19(2):112–23.
17. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, et al. A
new oncogene in human thyroid papillary carcinomas and their lymph-nodal
metastases. Nature. 1987;328(6126):170–2.
18. Kas K, Voz ML, Roijer E, Astrom AK, Meyen E, Stenman G, et al. Promoter
swapping between the genes for a novel zinc finger protein and β-catenin
in pleiomorphic adenomas with t(3;8)(p21;q12) translocations. Nat Genet.
1997;15(2):170–4.
19. Geurts JM, Schoenmakers EF, Roijer E, Stenman G, Van de Ven WJ. Expression
of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma
of the parotid gland. Cancer Res. 1997;57(1):13–7.
20. Sidhar SK, Clark J, Gill S, Hamoudi R, Crew AJ, Gwilliam R, et al. The t(X;
1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel
gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet. 1996;5(9):
1333–8.
21. Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA,
et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in
human secretory breast carcinoma. Cancer Cell. 2002;2(5):367–76.
22. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al.
PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science. 2000;
289(5483):1357–60.
23. French CA, Miyoshi I, Aster JC, Kubonishi I, Kroll TG, Dal Cin P, et al. BRD4
bromodomain gene rearrangement in aggressive carcinoma with translocation
t(15;19). Am J Pathol. 2001;159(6):1987–92.
24. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in
prostate cancer. Nat Rev Cancer. 2008;8(7):497–511.
25. Boveri T. Zur Frage der Entstehung maligner Tumoren. Gustav Fisher: Jena;
1914.
26. Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, Vardy LA, et al. Transcriptional
consequences of genomic structural aberrations in breast cancer. Genome
Res. 2011;21(5):676–87.
27. Yao F, Kausalya JP, Sia YY, Teo AS, Lee WH, Ong AG, et al. Recurrent fusion
genes in gastric cancer: CLDN18-ARHGAP26 induces loss of epithelial
integrity. Cell Rep. 2015;12(2):272–85.28. Dillon R, Nilsson CL, Shi SD, Lee NV, Krastins B, Greig MJ. Discovery of a
novel B-Raf fusion protein related to c-Met drug resistance. J Proteome Res.
2011;10(11):5084–94.
29. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. SLC45A3-ELK4
chimera in prostate cancer: spotlight on cis-splicing. Cancer Discov.
2012;2(7):582–5.
30. Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, et al.
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific
fusion transcript in prostate cancer. Cancer Res. 2009;69(7):2734–8.
31. Zhang Y, Gong M, Yuan H, Park HG, Frierson HF, Li H. Chimeric transcript
generated by cis-splicing of adjacent genes regulates prostate cancer cell
proliferation. Cancer Discov. 2012;2(7):598–607.
32. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, et al.
Genomic sequencing of colorectal adenocarcinomas identifies a recurrent
VTI1A-TCF7L2 fusion. Nat Genet. 2011;43(10):964–8.
33. Nome T, Hoff AM, Bakken AC, Rognum TO, Nesbakken A, Skotheim RI. High
frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel
fusion partner and splice variants. PLoS One. 2014;9(3), e91264.
34. Guerra E, Trerotola M, Dell’ Arciprete R, Bonasera V, Palombo B, El-Sewedy T,
et al. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel
oncogenic mechanism in human cancer. Cancer Res. 2008;68(19):8113–21.
35. Iyer MK, Chinnaiyan AM, Maher CA. ChimeraScan: a tool for identifying
chimeric transcription in sequencing data. Bioinformatics. 2011;27(20):2903–4.
36. Sboner A, Habegger L, Pflueger D, Terry S, Chen DZ, Rozowsky JS, et al.
FusionSeq: a modular framework for finding gene fusions by analyzing
paired-end RNA-sequencing data. Genome Biol. 2010;11(10):R104.
37. McPherson A, Hormozdiari F, Zayed A, Giuliany R, Ha G, Sun MG, et al. deFuse:
an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput
Biol. 2011;7(5):e1001138.
38. Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion
transcripts. Genome Biol. 2011;12(8):R72.
39. Torres-Garcia W, Zheng S, Sivachenko A, Vegesna R, Wang Q, Yao R, et al.
PRADA: pipeline for RNA sequencing data analysis. Bioinformatics. 2014;
30(15):2224–6.
40. Davidson NM, Majewski IJ, Oshlack A. JAFFA: high sensitivity transcriptome-
focused fusion gene detection. Genome Med. 2015;7(1):43.
41. Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, et al. A single-tube
multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
J Mol Diagn. 2014;16(2):229–43.
42. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, et al. Multiplexed gene
expression and fusion transcript analysis to detect ALK fusions in lung
cancer. J Mol Diagn. 2013;15(1):51–61.
43. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, et al. Identification
of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a
comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer
Res. 2012;18(24):6599–608.
44. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat Res. 2000;
462(2–3):247–53.
45. Mitelman F, Johansson B, Mertens FE. Mitelman Database of Chromosome
Aberrations and Gene Fusions in Cancer. Cancer Genome Anatomy Project;
2014. http://cgap.nci.nih.gov/Chromosomes/Mitelman.
46. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, et al.
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia.
2008;10(2):177–8.
47. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, et al.
TMPRSS2-ERG gene fusion causing ERG overexpression precedes
chromosome copy number changes in prostate carcinomas and paired
HGPIN lesions. Neoplasia. 2006;8(10):826–32.
48. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusions
between TMPRSS2 and ETS family genes in prostate cancer: frequency and
transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
Mod Pathol. 2007;20(9):921–8.
49. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication
of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate
cancer. Oncogene. 2008;27(3):253–63.
50. Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, et al. Characterization
of TMPRSS2-ETS gene aberrations in androgen-independent metastatic
prostate cancer. Cancer Res. 2008;68(10):3584–90.
51. Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, et al.
ERG rearrangement metastasis patterns in locally advanced prostate cancer.
Urology. 2010;75(4):762–7.
Kumar-Sinha et al. Genome Medicine  (2015) 7:129 Page 16 of 1852. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, et al. A causal
role for ERG in neoplastic transformation of prostate epithelium. Proc Natl
Acad Sci U S A. 2008;105(6):2105–10.
53. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, et al. A
fluorescence in situ hybridization screen for E26 transformation-specific
aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Cancer Res. 2008;68(18):7629–37.
54. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, et al.
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate
cancer. Cancer Res. 2006;66(7):3396–400.
55. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, et al.
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in
prostate cancer. Cancer Res. 2008;68(1):73–80.
56. Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jeronimo C,
Henrique R, et al. FLI1 is a novel ETS transcription factor involved in gene
fusions in prostate cancer. Genes Chromosomes Cancer. 2012;51(3):240–9.
57. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, et al.
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-
based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;
15(9):3143–9.
58. Bergethon K, Shaw AT, Ignatius Ou SH, Katayama R, Lovly CM, McDonald
NT, et al. ROS1 rearrangements define a unique molecular class of lung
cancers. J Clin Oncol. 2012;30:863–70.
59. Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, et al.
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008;10(3):
298–302.
60. Kimura H, Nakajima T, Takeuchi K, Soda M, Mano H, Iizasa T, et al. ALK fusion
gene positive lung cancer and 3 cases treated with an inhibitor for ALK
kinase activity. Lung Cancer. 2012;75(1):66–72.
61. Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E,
et al. Clinicopathologic features of non-small-cell lung cancer with EML4-
ALK fusion gene. Ann Surg Oncol. 2010;17(3):889–97.
62. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS,
et al. Clinical features and outcome of patients with non-small-cell lung
cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–53.
63. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al.
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1
cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22(4):
508–15.
64. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, et al. Fusion of KIF5B and
RET transforming gene in lung adenocarcinoma revealed from whole-
genome and transcriptome sequencing. Genome Res. 2011;22:436–45.
65. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1
and ALK fusions in lung cancer. Nat Med. 2012;18:378–81.
66. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al.
Identification of new ALK and RET gene fusions from colorectal and lung
cancer biopsies. Nat Med. 2012;18:382–4.
67. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al.
KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18:375–7.
68. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al.
Response to cabozantinib in patients with RET fusion-positive lung
adenocarcinomas. Cancer Discov. 2013;3(6):630–5.
69. Falchook GS, Ordonez NG, Bastida CC, Stephens PJ, Miller VA, Gaido L, et al.
Effect of the RET inhibitor Vandetanib in a patient with RET fusion-positive
metastatic non-small-cell lung cancer. J Clin Oncol. 2014. doi: 10.1200/JCO.
2013.50.5016.
70. Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The
distribution of BRAF gene fusions in solid tumors and response to targeted
therapy. Int J Cancer. 2015. doi: 10.1002/ijc.29825.
71. Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, et al. RNA-seq of 272
gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in
secondary glioblastomas. Genome Res. 2014;24(11):1765–73.
72. Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, et al.
BRAF alterations in primary glial and glioneuronal neoplasms of the central
nervous system with identification of 2 novel KIAA1549: BRAF fusion
variants. J Neuropathol Exp Neurol. 2012;71(1):66–72.
73. Tian Y, Rich BE, Vena N, Craig JM, Macconaill LE, Rajaram V, et al. Detection
of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded
pediatric low-grade gliomas. J Mol Diagn. 2011;13(6):669–77.
74. Lawson AR, Hindley GF, Forshew T, Tatevossian RG, Jamie GA, Kelly GP, et al.
RAF gene fusion breakpoints in pediatric brain tumors are characterized bysignificant enrichment of sequence microhomology. Genome Res. 2011;
21(4):505–14.
75. Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, et al.
BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade
astrocytoma. Clin Cancer Res. 2011;17(14):4790–8.
76. Cin H, Meyer C, Herr R, Janzarik WG, Lambert S, Jones DT, et al. Oncogenic
FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative
mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta
Neuropathol. 2011;121(6):763–74.
77. Jeuken JW, Wesseling P. MAPK pathway activation through BRAF gene
fusion in pilocytic astrocytomas; a novel oncogenic fusion gene with
diagnostic, prognostic, and therapeutic potential. J Pathol. 2010;222(4):
324–8.
78. Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, Resnick AC, et al.
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-
density single-nucleotide polymorphism-based genotype arrays results in a
novel BRAF fusion gene. Brain Pathol. 2009;19(3):449–58.
79. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP.
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives
to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic
astrocytoma. Oncogene. 2009;28(20):2119–23.
80. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, et al.
Tandem duplication producing a novel oncogenic BRAF fusion gene
defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–77.
81. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, et al.
Integrative analysis of the melanoma transcriptome. Genome Res. 2010;
20(4):413–27.
82. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K,
Shankar S, et al. Rearrangements of the RAF kinase pathway in prostate
cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793–8.
83. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM,
et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;
161(5):1215–28.
84. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al.
Recurrent R-spondin fusions in colon cancer. Nature. 2012;488(7413):660–4.
85. Tao J, Deng NT, Ramnarayanan K, Huang B, Oh HK, Leong SH, et al. CD44-
SLC1A2 gene fusions in gastric cancer. Sci Transl Med. 2011;3(77):77ra30.
86. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, et al.
Functionally recurrent rearrangements of the MAST kinase and Notch gene
families in breast cancer. Nat Med. 2011;17(12):1646–51.
87. Durinck S, Stawiski EW, Pavia-Jimenez A, Modrusan Z, Kapur P, Jaiswal BS,
et al. Spectrum of diverse genomic alterations define non-clear cell renal
carcinoma subtypes. Nat Genet. 2015;47:13–21.
88. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al.
Identification of targetable FGFR gene fusions in diverse cancers. Cancer
Discov. 2013;3(6):636–47.
89. Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, et al. The
landscape and therapeutic relevance of cancer-associated transcript fusions.
Oncogene. 2015;34:4845–54.
90. Parker BC, Engels M, Annala M, Zhang W. Emergence of FGFR family gene
fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol.
2014;232(1):4–15.
91. Persson F, Winnes M, Andren Y, Wedell B, Dahlenfors R, Asp J, et al. High-
resolution array CGH analysis of salivary gland tumors reveals fusion and
amplification of the FGFR1 and PLAG1 genes in ring chromosomes.
Oncogene. 2008;27(21):3072–80.
92. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming
fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;
337(6099):1231–5.
93. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al.
Frequent and focal FGFR1 amplification associates with therapeutically
tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med.
2010;2(62):62ra93.
94. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder
cancer. Hum Mol Genet. 2013;22(4):795–803.
95. Medves S, Demoulin JB. Tyrosine kinase gene fusions in cancer: translating
mechanisms into targeted therapies. J Cell Mol Med. 2011;16:237–48.
96. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009;
6(8):429–39.
97. Cavalheiro EA, Olney JW. Glutamate antagonists: deadly liaisons with cancer.
Proc Natl Acad Sci U S A. 2001;98(11):5947–8.
Kumar-Sinha et al. Genome Medicine  (2015) 7:129 Page 17 of 1898. Rzeski W, Turski L, Ikonomidou C. Glutamate antagonists limit tumor growth.
Proc Natl Acad Sci U S A. 2001;98(11):6372–7.
99. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al.
Metabolomic profiles delineate potential role for sarcosine in prostate
cancer progression. Nature. 2009;457(7231):910–4.
100. Yu J, Wu WK, Liang Q, Zhang N, He J, Li X, et al. Disruption of NCOA2 by
recurrent fusion with LACTB2 in colorectal cancer. Oncogene. 2015.
doi: 10.1038/onc.2015.72.
101. Annala M, Kivinummi K, Tuominen J, Karakurt S, Granberg K, Latonen L, et al.
Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
Oncotarget. 2015;6(8):6235–50.
102. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY,
et al. The genomic complexity of primary human prostate cancer. Nature.
2011;470(7333):214–20.
103. Skalova A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, et al.
Mammary analogue secretory carcinoma of salivary glands, containing the
ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity.
Am J Surg Pathol. 2010;34(5):599–608.
104. French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol.
2012;7:247–65.
105. French CA, Rahman S, Walsh EM, Kuhnle S, Grayson AR, Lemieux ME, et al.
NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a
novel oncogenic mechanism. Cancer Discov. 2014;4(8):928–41.
106. Fehr A, Roser K, Belge G, Loning T, Bullerdiek J. A closer look at Warthin
tumors and the t(11;19). Cancer Genet Cytogenet. 2008;180(2):135–9.
107. Martins C, Cavaco B, Tonon G, Kaye FJ, Soares J, Fonseca I. A study of
MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumor of
salivary glands. J Mol Diagn. 2004;6(3):205–10.
108. Seethala RR, Dacic S, Cieply K, Kelly LM, Nikiforova MN. A reappraisal of the
MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas. Am J
Surg Pathol. 2010;34(8):1106–21.
109. Achcar Rde O, Nikiforova MN, Dacic S, Nicholson AG, Yousem SA. Mammalian
mastermind like 2 11q21 gene rearrangement in bronchopulmonary
mucoepidermoid carcinoma. Hum Pathol. 2009;40(6):854–60.
110. O'Neill ID. Gefitinib as targeted therapy for mucoepidermoid carcinoma of
the lung: possible significance of CRTC1-MAML2 oncogene. Lung Cancer.
2009;64(1):129–30.
111. O'Neill ID. t(11;19) translocation and CRTC1-MAML2 fusion oncogene in
mucoepidermoid carcinoma. Oral Oncol. 2009;45(1):2–9.
112. Serra A, Schackert HK, Mohr B, Weise A, Liehr T, Fitze G. t(11;19)(q21;p12 ~
p13.11) and MECT1-MAML2 fusion transcript expression as a prognostic
marker in infantile lung mucoepidermoid carcinoma. J Pediatr Surg. 2007;
42(7):E23–29.
113. Lennerz JK, Perry A, Mills JC, Huettner PC, Pfeifer JD. Mucoepidermoid
carcinoma of the cervix: another tumor with the t(11;19)-associated
CRTC1-MAML2 gene fusion. Am J Surg Pathol. 2009;33(6):835–43.
114. Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK. CRTC1/
MAML2 fusion transcript in high grade mucoepidermoid carcinomas of
salivary and thyroid glands and Warthin's tumors: implications for histogenesis
and biologic behavior. Genes Chromosomes Cancer. 2007;46(7):708–15.
115. Kazakov DV, Vanecek T, Belousova IE, Mukensnabl P, Kollertova D, Michal M.
Skin-type hidradenoma of the breast parenchyma with t(11;19) translocation:
hidradenoma of the breast. Am J Dermatopathol. 2007;29(5):457–61.
116. Winnes M, Molne L, Suurkula M, Andren Y, Persson F, Enlund F, et al.
Frequent fusion of the CRTC1 and MAML2 genes in clear cell variants of
cutaneous hidradenomas. Genes Chromosomes Cancer. 2007;46(6):559–63.
117. Nakayama T, Miyabe S, Okabe M, Sakuma H, Ijichi K, Hasegawa Y, et al.
Clinicopathological significance of the CRTC3-MAML2 fusion transcript in
mucoepidermoid carcinoma. Mod Pathol. 2009;22(12):1575–81.
118. Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW, et al. Mucoepidermoid
carcinoma of lung: potential target of EGFR-directed treatment. Lung
Cancer. 2008;61(1):30–4.
119. Marchio C, Weigelt B, Reis-Filho JS. Adenoid cystic carcinomas of the breast
and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of
exocrine gland carcinomas). J Clin Pathol. 2010;63(3):220–8.
120. Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent
fusion of MYB and NFIB transcription factor genes in carcinomas of the
breast and head and neck. Proc Natl Acad Sci U S A. 2009;106(44):18740–4.
121. Leeman-Neill RJ, Kelly LM, Liu P, Brenner AV, Little MP, Bogdanova TI, et al.
ETV6-NTRK3 is a common chromosomal rearrangement in radiation-
associated thyroid cancer. Cancer. 2014;120(6):799–807.122. Boos LA, Dettmer M, Schmitt A, Rudolph T, Steinert H, Moch H, et al. Diagnostic
and prognostic implications of the PAX8-PPARγ translocation in thyroid
carcinomas-a TMA-based study of 226 cases. Histopathology. 2013;63(2):234–41.
123. Antonescu CR, Katabi N, Zhang L, Sung YS, Seethala RR, Jordan RC, et al.
EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell
carcinoma of salivary gland. Genes Chromosomes Cancer. 2011;50(7):559–70.
124. Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, et al. Exon array profiling
detects EML4-ALK fusion in breast, colorectal, and non-small cell lung
cancers. Mol Cancer Res. 2009;7(9):1466–76.
125. Marino-Enriquez A, Ou WB, Weldon CB, Fletcher JA, Perez-Atayde AR. ALK
rearrangement in sickle cell trait-associated renal medullary carcinoma.
Genes Chromosomes Cancer. 2011;50(3):146–53.
126. Debelenko LV, Raimondi SC, Daw N, Shivakumar BR, Huang D, Nelson M,
et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of
ALK-associated tumor spectrum. Mod Pathol. 2011;24(3):430–42.
127. Moller E, Stenman G, Mandahl N, Hamberg H, Molne L, van den Oord JJ,
et al. POU5F1, encoding a key regulator of stem cell pluripotency, is fused
to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of
the salivary glands. J Pathol. 2008;215(1):78–86.
128. Dessars B, De Raeve LE, El Housni H, Debouck CJ, Sidon PJ, Morandini R,
et al. Chromosomal translocations as a mechanism of BRAF activation in
two cases of large congenital melanocytic nevi. J Invest Dermatol. 2007;
127(6):1468–70.
129. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The
tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in
glioblastoma. J Clin Invest. 2013;123(2):855–65.
130. Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G,
et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant
medullary thyroid carcinoma cells. Endocr Relat Cancer. 2011;18(1):1–11.
131. Houvras Y. Completing the arc: targeted Inhibition of RET in medullary
thyroid cancer. J Clin Oncol. 2012;30(2):200–2.
132. Gautschi O, Zander T, Keller FA, Strobel K, Hirschmann A, Aebi S, et al. A
patient with lung adenocarcinoma and RET fusion treated with vandetanib.
J Thorac Oncol. 2013;8(5):e43–4.
133. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from
discovery to therapy in record time. Cancer Cell. 2010;18(6):548–51.
134. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-
ALK mutations in lung cancer that confer resistance to ALK inhibitors. N
Engl J Med. 2010;363(18):1734–9.
135. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic
strategies to overcome crizotinib resistance in non-small cell lung cancers
harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;
108(18):7535–40.
136. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B,
et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung
cancers. Sci Transl Med. 2012;4:120ra17.
137. Acquaviva J, He S, Zhang C, Jimenez JP, Nagai M, Sang J, et al. FGFR3
translocations in bladder cancer: differential sensitivity to HSP90 inhibition
based on drug metabolism. Mol Cancer Res. 2014;12(7):1042–54.
138. Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, et al.
ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by
targeting the IGF1R signaling pathway. Cancer Res. 2011;71(3):1060–70.
139. Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al.
Integrative clinical sequencing in the management of refractory or relapsed
cancer in youth. JAMA. 2015;314(9):913–25.
140. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI,
et al. Inhibition of BET recruitment to chromatin as an effective treatment
for MLL-fusion leukaemia. Nature. 2011;478(7370):529–33.
141. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET
bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell.
2011;146(6):904–17.
142. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, et al. Targeting Wnt-driven
cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U
S A. 2013;110(50):20224–9.
143. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al.
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men
with elevated serum PSA. Sci Transl Med. 2011;3(94):94ra72.
144. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, et al.
Characterization of ERG, AR and PTEN gene status in circulating tumor cells
from patients with castration-resistant prostate cancer. Cancer Res. 2009;
69(7):2912–8.
Kumar-Sinha et al. Genome Medicine  (2015) 7:129 Page 18 of 18145. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic
rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-
positive prostate cancer. Cancer Cell. 2011;19(5):664–78.
146. Chatterjee P, Choudhary GS, Alswillah T, Xiong X, Heston WD, Magi-Galluzzi
C, et al. The TMPRSS2-ERG gene fusion blocks XRCC4-mediated
nonhomologous end-joining repair and radiosensitizes prostate cancer cells
to PARP inhibition. Mol Cancer Ther. 2015;14(8):1896–906.
147. Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, et al.
PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion
gene-expressing and PTEN-deficient prostate cancer cells. PLoS One.
2013;8(4), e60408.
148. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C,
et al. Minimum information about a microarray experiment (MIAME)-toward
standards for microarray data. Nat Genet. 2001;29(4):365–71.
149. Kalyana-Sundaram S, Shanmugam A, Chinnaiyan AM. Gene Fusion Markup
Language: a prototype for exchanging gene fusion data. BMC Bioinformatics.
2012;13:269.
150. Campbell PJ, Stephens PJ, Pleasance ED, O'Meara S, Li H, Santarius T, et al.
Identification of somatically acquired rearrangements in cancer using
genome-wide massively parallel paired-end sequencing. Nat Genet. 2008;
40(6):722–9.
151. Ottaviani D, LeCain M, Sheer D. The role of microhomology in genomic
structural variation. Trends Genet. 2014;30(3):85–94.
152. Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE.
Proximity of chromosomal loci that participate in radiation-induced
rearrangements in human cells. Science. 2000;290(5489):138–41.
153. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al.
Induced chromosomal proximity and gene fusions in prostate cancer.
Science. 2009;326(5957):1230.
154. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptor-induced
chromosomal proximity and DNA breaks underlie specific translocations in
cancer. Cell. 2009;139(6):1069–83.
155. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive
genomic rearrangement acquired in a single catastrophic event during cancer
development. Cell. 2011;144(1):27–40.
156. Meyerson M, Pellman D. Cancer genomes evolve by pulverizing single
chromosomes. Cell. 2011;144(1):9–10.
157. Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first
century of human tumour virology. Nat Rev Cancer. 2010;10(12):878–89.
158. Peter M, Rosty C, Couturier J, Radvanyi F, Teshima H, Sastre-Garau X. MYC
activation associated with the integration of HPV DNA at the MYC locus in
genital tumors. Oncogene. 2006;25(44):5985–93.
159. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of
genomic integration sites of human papillomavirus genomes in epithelial
dysplasia and invasive cancer of the female lower genital tract. Cancer Res.
2004;64(11):3878–84.
160. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of
recurrent HBV integration in hepatocellular carcinoma. Nat Genet.
2012;44(7):765–9.
161. Schmitz M, Driesch C, Jansen L, Runnebaum IB, Durst M. Non-random
integration of the HPV genome in cervical cancer. PLoS One. 2012;7(6),
e39632.
162. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus
in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100.
163. Chung GT, Lung RW, Hui AB, Yip KY, Woo JK, Chow C, et al. Identification of
a recurrent transforming UBR5-ZNF423 fusion gene in EBV-associated
nasopharyngeal carcinoma. J Pathol. 2013;231(2):158–67.
